Skip to main content
  • Guideline Summary
  • NGC:008061

This guideline summary has been replaced by an updated version. Please update your bookmarks.

View the updated summary: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. NGC:010890

View all updated summaries in the Guideline Archive.

About NGC Guideline Summaries

NGC's guidelines summaries contain information systematically derived from original guidelines.

Guideline Summary FAQ


Guideline Summaries

New This Week

View more and sign up for our Newsletter

Get Adobe Reader